Fig 1.
The Motion Sickness Severity Scale (MSSS).
Participants completed the MSSS every 30 minutes of the boat trip.
Fig 2.
The Patient Global Impression of Severity scale (PGI-S).
Participants completed the PGI-S approximately 60 minutes after the conclusion of the boat trip.
Fig 3.
The Motion Sickness Assessment Questionnaire (MSAQ).
Participants completed the MSAQ approximately 60 minutes after the conclusion of the boat trip.
Fig 4.
Empirical Cumulative Distribution Functions (ECDFs) of MSSS scores plotted for each PGI-S severity level.
The empirical cumulative distribution functions of MSSS scores recorded by participants in each PGI-S severity level are plotted, with non-parametric kernel smoothing applied to produce curves. The order and separation of PGI-S-score-lines indicate that MSSS score distributions include greater proportions of high scores with increasing PGI-S severity level.
Table 1.
Mean MSSS, MSAQ and MSAQ subscale scores grouped by PGI-S severity level.
Mean questionnaire scores grouped by PGI-S severity level are reported for healthy participants without antiemetic treatment in the Motion Sifnos Study. Mean scores increase incrementally across the MSSS, MSAQ, and all subscales with increasing PGI-S severity levels.
Table 2.
Pearson correlations between PGI-S scores and other questionnaire scores.
Pearson correlations between PGI-S scores and scores reported on the other questionnaires are high or very high across all assessment instruments. For all Pearson correlation coefficients, p-value<0.0001.
Table 3.
Pearson correlations between MSAQ individual items, factors, and other questionnaires.
Pearson correlation coefficients between individual and grouped MSAQ items and the other questionnaires are presented in the table for the overall Motion Sifnos Study population, as well as for the placebo and Tradipitant treatment groups. High (r≥0.70) and very high (r>0.90) correlations are bolded.
Fig 5.
Scatterplots of MSSS scores paired to other questionnaire scores.
The top two panels present scatterplots of individual participants scores on the PGI-S and MSSS in the placebo group (A) and overall Motion Sifnos population (B). Scatterplots of individual participants scores on the PGI-S and MSAQ-GI (C) and MSAQ Total (D) are shown. A linear regression line with a 95% confidence interval (the shaded area) is superimposed on each scatterplot. The scatterplots of PGI-S scores and the corresponding scores on each of the other assessment instruments reveal the relationship and distribution of paired scores, which is strong in all four panels.
Table 4.
Differences in MSSS, MSAQ, and MSAQ subscale scores by PGI-S severity level.
Least-squared (LS) means differences and p-values are reported from one-way analyses of variance with the main effect of PGI-S conducted to evaluate differences in mean scores on the MSSS, MSAQ, and subscales for healthy participants without antiemetic treatment.